Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALENTINE trial of neoadjuvant patritumab deruxtecan with or without endocrine therapy for high-risk HR-positive/HER2-negative early breast cancer
2023-503403-28-00Phase 2Authorised
- Sponsor
- SOLTI
- Start
- Nov 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of patritumab deruxtecan in breast cancer (2 arms), sponsored by SOLTI. Primary endpoint: Pathologic complete response in breast and lymph nodes. Planned start Nov 2022; status: authorised.
02
Drugs
patritumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-503403-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503403-28-00.